Table of Content

Open Access iconOpen Access

ARTICLE

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Oncology Research 2016, 24(2), 73-80. https://doi.org/10.3727/096504016X14586627440156

Abstract

Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median overall survival for all patients was 7.4 months. The survival of patients who achieved CR and underwent allogeneic hematopoietic cell transplantation (allo-HCT) was higher than those who achieved CR and did not undergo allo-HCT (35.3 months vs. 16.8 months, p=0.057). The median duration of relapse-free survival was 12.7 months in the patients achieving CR. Older age at the time of AML relapse was associated with worse overall survival. The all-cause 4-week mortality rate was 4%, and the all-cause 8-week mortality rate was 13%. The findings of this study underscore the need for newer therapies, especially those that will improve the ability for patients with relapsed AML to achieve CR and to allow them to receive additional therapies.

Keywords


Cite This Article

APA Style
Im, A., Amjad, A., Agha, M., Raptis, A., Hou, J. et al. (2016). Mitoxantrone and etoposide for the treatment of acute myeloid leukemia patients in first relapse. Oncology Research, 24(2), 73-80. https://doi.org/10.3727/096504016X14586627440156
Vancouver Style
Im A, Amjad A, Agha M, Raptis A, Hou J, Farah R, et al. Mitoxantrone and etoposide for the treatment of acute myeloid leukemia patients in first relapse. Oncol Res. 2016;24(2):73-80 https://doi.org/10.3727/096504016X14586627440156
IEEE Style
A. Im et al., "Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse," Oncol. Res., vol. 24, no. 2, pp. 73-80. 2016. https://doi.org/10.3727/096504016X14586627440156



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 30

    View

  • 31

    Download

  • 0

    Like

Share Link